Extended Data Fig. 6: TPN2.0 reduces race-specific variance, particularly in populations with adverse outcomes.

The variance of the TPN composition values across races is calculated for both TPN2.0 and actual prescriptions. The calculation is stratified for patients with specific adverse outcomes and for those who were not diagnosed with any of the 16 adverse outcomes or congenital heart diseases (baseline) listed in Supplementary Table 3. The results indicate that actual prescriptions are not only associated with higher variance across races in baseline patients compared to TPN2.0 (~2x), but more so (>~4x) in patients with adverse outcomes. Refer to Supplementary Table 1 for the number of data points in each group. Data are presented as mean values +/− SEM.